DK1898945T3 - Luftvejsadministration af site-inaktiveret FVIIA ved inflammatoriske tilstande, der påvirker luftvejene - Google Patents

Luftvejsadministration af site-inaktiveret FVIIA ved inflammatoriske tilstande, der påvirker luftvejene

Info

Publication number
DK1898945T3
DK1898945T3 DK06795540.1T DK06795540T DK1898945T3 DK 1898945 T3 DK1898945 T3 DK 1898945T3 DK 06795540 T DK06795540 T DK 06795540T DK 1898945 T3 DK1898945 T3 DK 1898945T3
Authority
DK
Denmark
Prior art keywords
airways
site
inflammatory conditions
conditions affecting
airway administration
Prior art date
Application number
DK06795540.1T
Other languages
Danish (da)
English (en)
Inventor
Lars Otto Uttenthal
Original Assignee
Drugrecure Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure Aps filed Critical Drugrecure Aps
Application granted granted Critical
Publication of DK1898945T3 publication Critical patent/DK1898945T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
DK06795540.1T 2005-06-24 2006-06-23 Luftvejsadministration af site-inaktiveret FVIIA ved inflammatoriske tilstande, der påvirker luftvejene DK1898945T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
PCT/IB2006/002631 WO2006136963A2 (en) 2005-06-24 2006-06-23 Airway administration of site-inactivated fviia in inflammatory conditions affecting the respiratory tract

Publications (1)

Publication Number Publication Date
DK1898945T3 true DK1898945T3 (da) 2013-03-25

Family

ID=37570814

Family Applications (3)

Application Number Title Priority Date Filing Date
DK06795540.1T DK1898945T3 (da) 2005-06-24 2006-06-23 Luftvejsadministration af site-inaktiveret FVIIA ved inflammatoriske tilstande, der påvirker luftvejene
DK06795527.8T DK1896059T3 (da) 2005-06-24 2006-06-23 Luftvejsadministration af Tissue Factor Pathway Inhibitor ved inflammatoriske tilstande, der påvirker luftvejene
DK06808954.9T DK1906994T3 (da) 2005-06-24 2006-06-23 Luftvejsadministration af aktiveret protein C ved inflammatoriske tilstande, som angriber åndedrætsorganerne

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK06795527.8T DK1896059T3 (da) 2005-06-24 2006-06-23 Luftvejsadministration af Tissue Factor Pathway Inhibitor ved inflammatoriske tilstande, der påvirker luftvejene
DK06808954.9T DK1906994T3 (da) 2005-06-24 2006-06-23 Luftvejsadministration af aktiveret protein C ved inflammatoriske tilstande, som angriber åndedrætsorganerne

Country Status (14)

Country Link
US (3) US20100279925A1 (https=)
EP (3) EP1896059B1 (https=)
JP (3) JP2008543926A (https=)
KR (2) KR20080074085A (https=)
CN (2) CN101262880A (https=)
AU (2) AU2006260599A1 (https=)
BR (2) BRPI0611710A2 (https=)
CA (2) CA2612597C (https=)
DK (3) DK1898945T3 (https=)
IL (2) IL188220A0 (https=)
NO (2) NO20080434L (https=)
RU (2) RU2496515C2 (https=)
WO (3) WO2007012976A2 (https=)
ZA (2) ZA200800251B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101787B1 (en) * 2006-12-11 2013-09-18 Drugrecure ApS Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
AU2013286812B2 (en) 2012-07-04 2017-04-20 Zz Biotech Llc Treatment of inflammatory skin disorders
PT3137102T (pt) * 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
PL3131572T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany
WO2018053029A1 (en) * 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
EP0946715B1 (en) * 1996-11-08 2006-03-29 Oklahoma Medical Research Foundation Use of a modified protein c
WO1998032459A1 (en) * 1997-01-29 1998-07-30 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
WO2001057193A2 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
DE60138364D1 (de) * 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
AU2002338487A1 (en) * 2001-05-02 2002-11-11 Novo Nordisk A/S Modified fvii in treatment of ards
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
EP1446140A4 (en) * 2001-10-15 2007-03-07 Novartis Vaccines & Diagnostic TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR)
KR100674315B1 (ko) * 2002-02-08 2007-01-24 에스케이 주식회사 가열로 튜브 세척제 및 세척방법
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
DE602004019761D1 (de) 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
DK1791555T3 (da) * 2004-09-10 2013-06-10 Pharmaorigin Aps Fremgangsmåde til behandling af lokal tracheal, bronchial eller alveolær blødning eller hæmoptyse
US8563511B2 (en) 2004-10-06 2013-10-22 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Also Published As

Publication number Publication date
DK1906994T3 (da) 2014-07-21
WO2006136963A3 (en) 2007-07-12
DK1896059T3 (da) 2013-04-08
ZA200800251B (en) 2009-04-29
EP1898945B1 (en) 2012-12-19
CA2612646C (en) 2015-11-24
IL188221A0 (en) 2008-03-20
WO2007012976A3 (en) 2007-07-12
JP2008543925A (ja) 2008-12-04
AU2006273696B2 (en) 2012-08-30
KR20080071116A (ko) 2008-08-01
HK1114567A1 (en) 2008-11-07
BRPI0611710A2 (pt) 2011-12-20
IL188220A0 (en) 2008-03-20
NO20080434L (no) 2008-03-17
JP2008543926A (ja) 2008-12-04
BRPI0613137A2 (pt) 2010-12-21
NO20080433L (no) 2008-03-19
RU2496515C2 (ru) 2013-10-27
JP2013151510A (ja) 2013-08-08
RU2008102656A (ru) 2009-07-27
ZA200800255B (en) 2009-04-29
RU2008102655A (ru) 2009-07-27
US20100279925A1 (en) 2010-11-04
US20100160218A1 (en) 2010-06-24
US8088728B2 (en) 2012-01-03
AU2006273696A1 (en) 2007-02-01
EP1898945A2 (en) 2008-03-19
WO2007012976A2 (en) 2007-02-01
WO2006136962A3 (en) 2007-07-12
CA2612646A1 (en) 2006-12-28
EP1906994A2 (en) 2008-04-09
EP1896059B1 (en) 2012-12-19
RU2496516C2 (ru) 2013-10-27
EP1906994B1 (en) 2014-04-23
CN101262879A (zh) 2008-09-10
EP1896059A2 (en) 2008-03-12
CA2612597A1 (en) 2007-02-01
CN101262879B (zh) 2013-04-10
US20100297099A1 (en) 2010-11-25
CN101262880A (zh) 2008-09-10
WO2006136963A2 (en) 2006-12-28
KR20080074085A (ko) 2008-08-12
AU2006260599A1 (en) 2006-12-28
WO2006136962A2 (en) 2006-12-28
CA2612597C (en) 2015-03-31

Similar Documents

Publication Publication Date Title
EE00721U1 (et) Inhalaatori loendur
DK1984009T3 (da) Farmaceutiske sammensætninger med forbedret stabilitet
ATE469664T1 (de) Vernebler
EP3777939C0 (en) NASAL ROYALTY
PL1883439T3 (pl) Nebulizer
DK2170280T3 (da) En inhalerbar sammensætning omfattende nikotin
ATE502666T1 (de) Inhalator
BRPI0716318A2 (pt) Faixa compressora
DK1984503T3 (da) Modificeret koaguleringsfaktor VIIa med forlænget halvliv
DE502005010604D1 (de) Strömungsarbeitsmaschine
CL2007002783S1 (es) Inhalador multidosis.
DE602007006263D1 (de) Turbomaschine
EP1782832A4 (en) MEANS FOR THE TREATMENT OF DIABETES
EP2067796A4 (en) POLYMERIZABLE COMPOUND AND POLYMERIZABLE COMPOSITION
DK2018158T3 (da) Ny racecadotril administrationsform
DE602007002345D1 (de) Kompressor
EP2000671A4 (en) COMPRESSOR
DE602007013317D1 (de) Inhalator
EP2009285A4 (en) COMPRESSOR
BRPI0814248A2 (pt) Inalador
FI20055630L (fi) Kasvonaamio
DE602005026122D1 (de) Inhalator
DK1927646T3 (da) Odoriseringsmiddel med forbedret stabilitet
EP1795701A4 (en) FLUID MACHINE
DK1898945T3 (da) Luftvejsadministration af site-inaktiveret FVIIA ved inflammatoriske tilstande, der påvirker luftvejene